In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

"CH and New GSK are two strong businesses that the market currently values far below their true potential. In our view, they warrant a combined valuation >45% higher than GSK's valuation today ...

but Novartis has a very strong track record in maximising the value from cancer drugs, including extending licences into new niche therapy areas. Novartis also has opt-in rights for GSK's current ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

This is one of GSK’s main value drivers at this stage ... This segment also grew, mainly due to their expanded approvals for new indications in the US and Europe. Lastly, GSK’s general ...

We are holding firm to GSK’s fair value estimate and continue to view the stock as undervalued with the market likely missing the firm’s growth potential, partially driven by new products like ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

PFG Investments LLC lifted its position in GSK plc (NYSE:GSK – Free Report) by 8.5% in the 3rd quarter, Holdings Channel.com ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from ...